The implications of biologic therapy in ankylosing spondylitis: comment on the articles by Brandt et al and Braun et al

Comment

Ravik Mascarenhas et al. Arthritis Rheum. 2004 Jul.

. 2004 Jul;50(7):2376-7; author reply 2377-8.

doi: 10.1002/art.20343.

No abstract available

Comment on

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Brandt J, et al. Arthritis Rheum. 2003 Jun;48(6):1667-75. doi: 10.1002/art.11017. Arthritis Rheum. 2003. PMID: 12794835 Clinical Trial.
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Braun J, et al. Arthritis Rheum. 2003 Aug;48(8):2224-33. doi: 10.1002/art.11104. Arthritis Rheum. 2003. PMID: 12905476 Clinical Trial.